0.38
-5.00%
Close of 5 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GlucoTrack
From its filings with the US Securities and Exchange Commission
GlucoTrack is based in Rutherford, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GCTK. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2019, it reported revenue of $208,000. By region, Europe [Member] accounted for 100.2%, followed by Asia and Pacific [Member] at 0.1%.
Chief Executive Officer and intends to develop the technology to address the growing Type 1 and Type 2 diabetes market.
This latter approach is of importance for patients with diabetes already contemplating spinal cord stimulation therapy for their condition.
US adults ages 18 years or older, there were 1.5 million new cases of diabetes diagnosed in 2023.
We believe that a significant market opportunity exists for an innovative CGM device that addresses the remaining barriers to adoption.
The Company conducted its own market research studies in 2024 and 2025 to validate its belief that these findings are still relevant.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 9 Apr 2013
- Employees
- 3
- Website
- integrity-app.com ↗
- Head office
- 301 RT 17 NORTH, RUTHERFORD, NJ, 07070
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Paul GoodePresident, Chief Executive Officer, Director, since 2020$350,000
- Mr. Peter WulffChief Financial Officer, Treasurer, Secretary
- Mr. Andrew BaloIndependent Director$53,022
- Dr. Victoria CarrbrendelIndependent Director
- Ms. Erin CarterIndependent Director$100,000
- Mr. Luis MalaveIndependent Director$120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GlucoTrack designs non-invasive glucose monitoring devices for diabetes patients.
- The company employs three full-time staff members in Rutherford.
- Cloud-based solutions provide real time data driven personalized tools.
Weaknesses
- The firm has only three employees for its operations.
- Development of the implantable continuous glucose monitor is ongoing.
- Reliance on two specific products limits current revenue streams.
Opportunities
- Expanding the non-invasive monitor market for Type II diabetes.
- Targeting insulin-dependent Type II patients with new devices.
- Growing demand for non-invasive glucose monitoring solutions globally.
Threats
- Competitors may develop superior non-invasive glucose monitoring technologies.
- Regulatory hurdles could delay the implantable monitor launch.
- Market adoption of non-invasive devices remains uncertain for users.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.